Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer

<p>We sought information worldwide on mortality according to assigned treatment in all randomized trials that began before 1985 of adjuvant tamoxifen or cytotoxic therapy for early breast cancer (with or without regional lymph-node involvement). Coverage was reasonably complete for most countr...

Bibliografski detalji
Glavni autor:	Early Breast Cancer Trialists' Collaborative Group
Daljnji autori:	Henderson, I
Format:	Journal article
Jezik:	English
Izdano:	Massachusetts Medical Society 1988

Slični predmeti

Tamoxifen for early breast cancer: an overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group
Izdano: (1998)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2011)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
od: Early Breast Cancer Trialists’ Collaborative Group
Izdano: (2017)

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2022)

Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials
od: Early Breast Cancer Trialists' Collaborative Group
Izdano: (1995)

Polychemotherapy for early breast cancer: an overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group
Izdano: (1998)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2005)

Ovarian ablation in early breast cancer: overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group
Izdano: (1996)

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2008)

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2005)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2014)

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
od: Early Breast Cancer Trialists’ Collaborative group (EBCTCG)
Izdano: (2021)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2011)

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Izdano: (2011)

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
od: Early Breast Cancer Trialist's Collaborative Group
Izdano: (1992)

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
od: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Izdano: (2010)

EFFECTS OF ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN EARLY BREAST-CANCER - AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 28,896 WOMEN
od: Peto, R
Izdano: (1989)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
od: Ana D. Pinzón-García, i dr.
Izdano: (2021-10-01)

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
od: Jaime D. Lewis, i dr.
Izdano: (2014-11-01)

Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
od: Mustafa Al-Mubarak, i dr.
Izdano: (2014-01-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
od: Vrbavac Milenko, i dr.
Izdano: (2002-01-01)

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
od: Pan, H, i dr.
Izdano: (2017)

Evaluation of Saline Sonohysterography Findings in Patients with Breast Cancer Receiving Tamoxifen Adjuvant Therapy
od: Maryam Rahmani, i dr.
Izdano: (2016-12-01)

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
od: Davies, C, i dr.
Izdano: (1998)

Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells
od: Mohamed Alitheen, Noorjahan Banu, i dr.
Izdano: (2015)

Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)
od: The Society of Breast Cancer of China Anti-Cancer Association, Breast Cancer Study Group Along Yangtze River
Izdano: (2022-03-01)

WITHDRAWN: Tamoxifen for early breast cancer.
od: Clarke, M
Izdano: (2008)

Screening and early diagnosis of breast cancer in China: a practice guideline
od: The Society of Breast Cancer, China Anti-Cancer Association
Izdano: (2022-04-01)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
od: Gelber, R, i dr.
Izdano: (1996)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
od: Abahssain Halima, i dr.
Izdano: (2010-08-01)

Early and late tamoxifen resistance in breast cancer
od: Abu Rabi Z., i dr.
Izdano: (2010-01-01)

The endometrium in women receiving adjuvant tamoxifen therapy after surgical treatment of breast cance
od: E V Dmitrieva, i dr.
Izdano: (2013-12-01)

The Effect of Canertinib on Sensitivity of Cytotoxic Drugs in Tamoxifen-Resistant Breast Cancer Cells In Vitro
od: Hesham A. M. Gomaa, i dr.
Izdano: (2018-01-01)

Adjuvant therapy for early breast cancer
od: I. V. Vysotskaya
Izdano: (2014-07-01)

Variation in use of adjuvant tamoxifen.
od: Davies, C, i dr.
Izdano: (1998)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
od: Andy Göbel, i dr.
Izdano: (2019-06-01)

Tamoxifen for Breast Cancer
od: A Karn, i dr.
Izdano: (2010-03-01)

Tamoxifen in breast conservation therapy.
od: Lee, K, i dr.
Izdano: (1995)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
od: Dowsett, M, i dr.
Izdano: (2009)

Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy
od: Lim, I-Liang, i dr.
Izdano: (2018)